Star Combo Pharma Limited (ASX:S66)
Australia
· Delayed Price · Currency is AUD 0.1150
0.00 (0.00%)
Apr 9, 2025, 3:03 PM AEST
Star Combo Pharma Income Statement
Financials in millions AUD. Fiscal year is July - June.
Millions AUD. Fiscal year is Jul - Jun.
Fiscal Year | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | 2015 - 2019 |
|---|---|---|---|---|---|---|---|
Period Ending | Dec '24 Dec 31, 2024 | Jun '24 Jun 30, 2024 | Jun '23 Jun 30, 2023 | Jun '22 Jun 30, 2022 | Jun '21 Jun 30, 2021 | Jun '20 Jun 30, 2020 | 2015 - 2019 |
| Operating Revenue | 29.53 | 26.02 | 24.7 | 22.88 | 26.72 | 38.84 | Upgrade
|
| Other Revenue | 0.03 | - | - | 0.08 | 0.24 | 0.25 | Upgrade
|
| Revenue | 29.56 | 26.02 | 24.7 | 22.96 | 26.97 | 39.08 | Upgrade
|
| Revenue Growth (YoY) | 16.07% | 5.34% | 7.57% | -14.86% | -31.00% | 81.74% | Upgrade
|
| Cost of Revenue | 23.26 | 20.3 | 19.91 | 18.79 | 23.54 | 34.91 | Upgrade
|
| Gross Profit | 6.3 | 5.71 | 4.79 | 4.17 | 3.43 | 4.17 | Upgrade
|
| Selling, General & Admin | 5.44 | 4.84 | 3.79 | 4.54 | 5.09 | 5.73 | Upgrade
|
| Other Operating Expenses | -0.24 | -0.2 | -0.16 | -0.3 | - | - | Upgrade
|
| Operating Expenses | 5.45 | 4.79 | 3.66 | 4.24 | 5.41 | 5.77 | Upgrade
|
| Operating Income | 0.85 | 0.92 | 1.12 | -0.06 | -1.98 | -1.6 | Upgrade
|
| Interest Expense | -0.19 | -0.2 | -0.19 | -0.17 | -0.24 | -0.51 | Upgrade
|
| Interest & Investment Income | 0.26 | 0.26 | 0.13 | 0.05 | 0.11 | 0 | Upgrade
|
| Currency Exchange Gain (Loss) | 0.16 | 0.01 | -0.05 | 0.05 | -0.05 | -0.02 | Upgrade
|
| Other Non Operating Income (Expenses) | - | 0 | - | 0 | - | - | Upgrade
|
| EBT Excluding Unusual Items | 1.09 | 1 | 1.02 | -0.14 | -2.16 | -2.12 | Upgrade
|
| Impairment of Goodwill | - | - | - | - | -6.34 | - | Upgrade
|
| Gain (Loss) on Sale of Assets | - | - | - | -0.09 | - | - | Upgrade
|
| Asset Writedown | - | - | -4.41 | -1.46 | - | - | Upgrade
|
| Legal Settlements | - | - | -0.06 | - | - | - | Upgrade
|
| Other Unusual Items | - | - | - | 0.6 | 1.04 | 1.22 | Upgrade
|
| Pretax Income | 1.09 | 1 | -3.45 | -1.08 | -7.46 | -0.91 | Upgrade
|
| Income Tax Expense | 0.19 | 0.25 | 0.55 | -0.39 | 0.41 | -0.56 | Upgrade
|
| Net Income | 0.9 | 0.75 | -4 | -0.7 | -7.88 | -0.35 | Upgrade
|
| Net Income to Common | 0.9 | 0.75 | -4 | -0.7 | -7.88 | -0.35 | Upgrade
|
| Net Income Growth | 85.09% | - | - | - | - | - | Upgrade
|
| Shares Outstanding (Basic) | 135 | 135 | 135 | 135 | 135 | 91 | Upgrade
|
| Shares Outstanding (Diluted) | 135 | 135 | 135 | 135 | 135 | 91 | Upgrade
|
| Shares Change (YoY) | - | - | 0.37% | -0.15% | 47.45% | 11.29% | Upgrade
|
| EPS (Basic) | 0.01 | 0.01 | -0.03 | -0.01 | -0.06 | -0.00 | Upgrade
|
| EPS (Diluted) | 0.01 | 0.01 | -0.03 | -0.01 | -0.06 | -0.00 | Upgrade
|
| Free Cash Flow | 4.15 | -1.76 | -0.85 | -6.76 | -6.93 | -3.74 | Upgrade
|
| Free Cash Flow Per Share | 0.03 | -0.01 | -0.01 | -0.05 | -0.05 | -0.04 | Upgrade
|
| Dividend Per Share | 0.004 | 0.004 | - | - | - | - | Upgrade
|
| Gross Margin | 21.32% | 21.96% | 19.38% | 18.18% | 12.72% | 10.67% | Upgrade
|
| Operating Margin | 2.89% | 3.55% | 4.55% | -0.28% | -7.34% | -4.09% | Upgrade
|
| Profit Margin | 3.04% | 2.87% | -16.21% | -3.03% | -29.20% | -0.89% | Upgrade
|
| Free Cash Flow Margin | 14.03% | -6.76% | -3.44% | -29.45% | -25.68% | -9.56% | Upgrade
|
| EBITDA | 1.77 | 1.73 | 1.63 | 0.37 | -1.54 | -1.14 | Upgrade
|
| EBITDA Margin | 6.00% | 6.65% | 6.59% | 1.59% | -5.70% | -2.91% | Upgrade
|
| D&A For EBITDA | 0.92 | 0.81 | 0.51 | 0.43 | 0.44 | 0.46 | Upgrade
|
| EBIT | 0.85 | 0.92 | 1.12 | -0.06 | -1.98 | -1.6 | Upgrade
|
| EBIT Margin | 2.89% | 3.55% | 4.55% | -0.28% | -7.34% | -4.09% | Upgrade
|
| Effective Tax Rate | 17.35% | 25.35% | - | - | - | - | Upgrade
|
Source: S&P Global Market Intelligence. Standard template. Financial Sources.